查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2002902

胃腸道疾病治療市場：2026年至2032年全球市場預測（按適應症、藥物類別、給藥途徑、劑型、分銷管道和最終用戶分類）

Gastrointestinal Diseases Therapeutics Market by Indication, Drug Class, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胃腸道疾病治療市場價值將達到 435.2 億美元，到 2026 年將成長至 453 億美元，到 2032 年將達到 577.1 億美元，複合年成長率為 4.11%。

主要市場統計數據
基準年 2025 435.2億美元
預計年份：2026年 453億美元
預測年份 2032 577.1億美元
複合年成長率 (%) 4.11%

本書以簡潔明了的方式概述了正在重新定義胃腸道疾病治療策略的臨床、商業性和營運趨勢。

目前胃腸道治療正處於臨床複雜性、技術創新以及支付方和監管機構不斷變化的期望交匯點。生物製劑的進步、人們對微生物組日益成長的興趣以及精準診斷的複興正在重塑從酸相關疾病到發炎性腸道疾病等多種疾病的研發重點。同時，醫療保健系統要求提供更清晰的真實世界價值證據，這正在改變臨床項目的規劃方式和商業化策略的優先順序。

前瞻性地整合科學、監管和商業性因素，推動胃腸道治療藥物的研發和交付發生根本性變革。

在科學突破、監管進步和醫療模式轉變的推動下，消化器官系統治療領域正經歷一場變革。首先，生物製藥平台和標靶免疫調節劑的成熟正促使研發重點轉向精確的作用機制。尤其是在發炎性腸道疾病領域，抗整合素藥物和白細胞介素抑制劑徹底改變了治療流程。同時，人們對腸道微生物組的重新關注也推動了對基於微生物組的療法和非常規干預措施的投資，這些療法有望提供除傳統小分子化合物和質子幫浦阻斷劑之外的全新治療方法。

對近期關稅變化如何重塑消化器官系統治療藥物的供應鏈、生產決策和商業談判進行策略評估。

美國將於2025年實施新的關稅措施，這些措施正對全球消化器官系統藥物的供應鏈、籌資策略和成本結構產生連鎖反應。關稅調整將影響活性藥物成分的成本，尤其是那些從海外供應商採購的成分，這可能會增加依賴跨境生產或大規模進口原料的製造商的價格壓力。因此，各公司需要重新審視其籌資策略和合約條款，以確保在確保產品品質和供應連續性的同時，獲利。

詳細的細分分析突顯了臨床、製藥和分銷管道中的差異因素，這些因素決定了每個治療領域的引入途徑和商業化優先事項。

細分市場層面的洞察揭示了不同適應症、藥物類別、給藥途徑、分銷管道、劑型和終端用戶之間存在的細微機會和限制因素。就適應症而言，酸相關疾病包括消化不良、胃食道逆流和消化性潰瘍，每種疾病都有其獨特的診斷和治療模式。另一方面，感染性胃腸炎涵蓋細菌性、感染疾病和病毒性胃腸炎，每種疾病對急性期管理和合理使用抗生素的影響各不相同。發炎性腸道疾病分為克隆氏症和潰瘍性大腸炎，其治療途徑包括手術和生物製藥。此外，大腸激躁症分為便秘型、腹瀉型和混合型，每種類型都需要針對特定症狀採取個別化治療方案。

區域比較觀點揭示了世界各地市場在監管、支付方和基礎設施方面的差異，這些差異影響著市場的存取、採用和供應策略。

區域趨勢反映了法律規範、醫療服務體系和患者族群特徵的差異，對制定研發重點和打入市場策略至關重要。在美洲，完善的臨床研究基礎設施、成熟的支付體系和先進的專科醫療網路為創新生物製藥和複雜治療方法的推廣應用提供了支持，但也帶來了嚴格的證據要求和價格壓力。因此，製造商必須優先考慮可靠的臨床終點和衛生經濟學證據，以確保其產品在這些市場獲得處方藥資格和報銷。

整合企業策略和生態系統夥伴關係，揭示創新、製造和數位整合如何重塑該領域的競爭優勢。

消化器官系統療法領域的企業發展趨勢反映了廣泛的策略立場，涵蓋了從創新驅動型生物技術公司到大規模製造商和專業合約服務供應商。創新公司專注於開發下一代生物製劑、標靶小分子化合物和基於微生物組的治療方法，通常利用精準醫療方法和生物標記主導的臨床試驗來識別對治療有反應的患者群體。這些公司經常與臨床研究網路和學術機構建立策略夥伴關係，以加速概念驗證(PoC) 研究並檢驗差異化的臨床終點。

以營運為重點的建議，整合供應鏈韌性、證據一致性和交付創新，以增強消化器官系統治療的臨床和商業性成果。

行業領導者應採取一系列切實可行的措施，將科學進步轉化為永續的商業性成果和更佳的患者照護。首先，他們應優先考慮供應商，並協商靈活的合約來降低關稅和地緣政治風險。投資雙源策略並加強與契約製造的關係，將有助於降低脆弱性，並確保臨床和商業性供應的連續性。

採用透明的多來源調查方法，結合文獻整合、專家參與和情境分析，以檢驗策略見解和建議。

本分析的調查方法整合了多種證據來源和迭代檢驗步驟，以確保其穩健性和有效性。首先，透過全面的二次檢索，整合了同儕審查的臨床文獻、監管指南、專利申請和治療指南，建立了關於治療機制、臨床終點和標準實踐的基於事實的基準。這項基礎性工作確定了關鍵的知識缺口，並明確了後續主要檢索的優先順序。

簡明扼要的結論強調，需要採取區域導向的綜合方法來應對策略挑戰，並將創新轉化為對患者的影響。

總之，消化器官系統治療領域正受到多種因素的共同影響而重組，這些因素包括生物製劑和微生物組研究領域的科學創新、監管機構對真實世界證據的重視、支付方對價值期望的轉變，以及供應鏈和政策變化帶來的營運壓力。應對這些變化需要製定一項涵蓋早期臨床試驗設計、生產規劃和市場准入談判的綜合策略。那些積極主動地將證據產生與支付方需求結合、實現供應鏈多元化並投資於給藥方法創新的機構，將在改善患者療效的同時，獲得競爭優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：胃腸道疾病治療藥物市場：依適應症分類

  • 與酸相關的疾病
    • 消化不良
    • 胃食道逆流症
    • 消化性潰瘍
  • 傳染性腸胃炎
    • 細菌性腸胃炎
    • 寄生蟲感染疾病
    • 病毒性腸胃炎
  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 大腸激躁症
    • 便秘型
    • 腹瀉型
    • 混合型

第9章：胃腸道藥物市場：依藥物類別分類

  • 氨基水楊酸類藥物
  • 抗生素
    • Ciprofloxacin
    • 甲硝唑
    • Rifaximin
  • 止瀉
  • 解痙藥
  • 生物製藥
    • 整合素抑制劑
    • 抗腫瘤壞死因子製劑
    • 白細胞介素抑制劑
  • H2受體拮抗劑
  • 瀉藥
  • 質子幫浦阻斷劑

第10章：胃腸道疾病治療藥物市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第11章 以劑型分類的胃腸道疾病治療藥物市場

  • 注射液
  • 口服粉劑
  • 口服懸浮液
  • 片劑和膠囊

第12章：胃腸道疾病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：胃腸道疾病治療市場：依最終使用者分類

  • 診所
  • 家庭醫療保健
  • 醫院

第14章：胃腸道疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：胃腸道疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：胃腸道藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國胃腸道疾病治療市場

第18章：中國胃腸道藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring BV
  • Gilead Sciences, Inc.
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-957C47F91DC1

The Gastrointestinal Diseases Therapeutics Market was valued at USD 43.52 billion in 2025 and is projected to grow to USD 45.30 billion in 2026, with a CAGR of 4.11%, reaching USD 57.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 43.52 billion
Estimated Year [2026] USD 45.30 billion
Forecast Year [2032] USD 57.71 billion
CAGR (%) 4.11%

An incisive introduction outlining evolving clinical, commercial, and operational dynamics that are redefining therapeutic strategies across gastrointestinal disease care

The gastrointestinal therapeutics landscape sits at the intersection of clinical complexity, technological innovation, and evolving payer and regulatory expectations. Advances in biologics, growing attention to the microbiome, and a resurgence in precision diagnostics have collectively reshaped development priorities for conditions ranging from acid-related disorders to inflammatory bowel disease. At the same time, healthcare systems are demanding clearer evidence of real-world value, which is changing how clinical programs are designed and how commercialization strategies are prioritized.

Against this backdrop, stakeholders must reconcile short-term operational challenges with long-term therapeutic opportunity. Supply chain resiliency, regulatory agility, and differentiated clinical endpoints are increasingly central to program viability. Moreover, patient-centric care models and digital health integrations are redefining adherence, monitoring, and outcome measurement for chronic gastrointestinal conditions. Consequently, decision-makers need an integrated view that links clinical innovation with commercial viability and practical deployment in hospitals, clinics, and home healthcare environments.

This executive summary distills core dynamics shaping therapeutic development, delivery, and market access across key indications and product classes. It highlights structural shifts in demand, regulatory and policy influences, and actionable imperatives for industry leaders. By synthesizing clinical trends with operational and commercial realities, the narrative aims to equip executives and investors with a focused perspective for prioritizing investment, structuring partnerships, and accelerating patient impact.

A forward-looking synthesis of scientific, regulatory, and commercial forces that are driving fundamental transformation across gastrointestinal therapeutics development and delivery

The landscape of gastrointestinal therapeutics is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing care models. First, the maturation of biologic platforms and targeted immunomodulators is redirecting R&D toward precise mechanisms of action, particularly for inflammatory bowel disease where anti-integrin agents and interleukin inhibitors have altered treatment algorithms. At the same time, renewed interest in the gut microbiome has catalyzed investment in microbiome therapeutics and nontraditional interventions, which promise new modalities beyond classic small molecules and proton pump inhibitors.

Concurrently, regulatory authorities are emphasizing adaptive pathways and real-world evidence, which is shaping study design and post-market commitments. This regulatory shift favors programs that integrate pragmatic endpoints, longitudinal patient monitoring, and health economics analyses early in development. Moreover, the distribution and delivery models are evolving; telehealth and remote patient monitoring are increasing the feasibility of home healthcare administration for selected therapies, while hospital-based specialty pharmacies continue to play a pivotal role for complex biologics.

Finally, commercial dynamics are shifting as payers insist on demonstrable value and cost-effectiveness. Manufacturers are responding with innovative pricing and evidence-generation strategies, including outcomes-based contracting and risk-sharing arrangements. Taken together, these shifts demand integrated strategies that span clinical development, regulatory engagement, supply chain planning, and payer dialogue in order to translate scientific advances into sustainable patient access and commercial success.

A strategic assessment of how recent tariff shifts reshape supply chains, manufacturing decisions, and commercial negotiations for gastrointestinal therapeutics

The introduction of new tariff measures in the United States in 2025 has implications that ripple across global supply chains, procurement strategies, and cost structures for gastrointestinal therapeutics. Tariff adjustments influence the cost of active pharmaceutical ingredients, particularly those sourced from international suppliers, and can increase the price pressure on manufacturers who rely on cross-border manufacturing and bulk raw material imports. Consequently, firms must reassess sourcing strategies and contract terms to preserve margins while maintaining product quality and continuity of supply.

In addition to direct cost implications, tariffs can accelerate strategic shifts in manufacturing geography and vertical integration. Companies may respond by nearshoring production of key intermediates, expanding domestic contract manufacturing capacity, or negotiating longer-term supplier agreements to dampen price volatility. These operational responses often require capital expenditure and longer lead times, and they can also affect timelines for clinical supply and commercial rollouts. Moreover, tariff-related cost increases may influence pricing negotiations with payers and hospital systems, prompting manufacturers to invest proactively in value demonstrations and real-world evidence to justify pricing decisions.

Policy uncertainty stemming from tariff regimes also impacts investor sentiment and M&A activity. Some investors may demand clearer visibility on supply chain risk mitigation before committing to sizeable transactions, while others may view tariffs as a catalyst for consolidation and strategic partnerships that secure localized manufacturing. Ultimately, companies that adopt a multifaceted response-combining supplier diversification, contractual protections, and transparent engagement with payers and purchasers-will be better positioned to manage the cumulative impacts while protecting patient access to essential gastrointestinal therapies.

Detailed segmentation analysis highlighting clinical, formulation, and channel differentiators that determine adoption pathways and commercialization priorities across therapeutic categories

Segment-level insights reveal nuanced opportunities and constraints across indications, drug classes, routes of administration, distribution channels, dosage forms, and end users. In indications, acid-related disorders encompass dyspepsia, gastroesophageal reflux disease, and peptic ulcer disease each with distinctive diagnostic and treatment patterns, while infectious gastroenteritis spans bacterial gastroenteritis, parasitic infections, and viral gastroenteritis that differ in acute management and antimicrobial stewardship implications. Inflammatory bowel disease bifurcates into Crohn's disease and ulcerative colitis with divergent surgical and biologic treatment pathways, and irritable bowel syndrome divides into constipation-predominant, diarrhea-predominant, and mixed type presentations that require personalized symptom-targeted approaches.

From a drug class perspective, traditional categories such as aminosalicylates, antibiotics, antidiarrheals, antispasmodics, H2 receptor antagonists, laxatives, and proton pump inhibitors continue to serve core therapeutic needs, while biologics and their subtypes-including anti-integrin agents, anti-tumor necrosis factor agents, and interleukin inhibitors-drive differentiated value in moderate-to-severe inflammatory conditions. Among antibiotics, agents like ciprofloxacin, metronidazole, and rifaximin play specific roles in treating distinct infectious etiologies, which underscores the importance of stewardship and resistance monitoring. Routes of administration, whether oral, parenteral, or topical, influence patient adherence, care setting requirements, and formulation innovation priorities.

Distribution channels such as hospital pharmacy, online pharmacy, and retail pharmacy each impose different commercial and regulatory dynamics that affect reimbursement, patient access, and adherence. Dosage form considerations-injectable solution, oral powder, oral suspension, and tablet capsule-shape manufacturing complexity, cold chain needs, and opportunities for delivery innovation. Finally, end-user segmentation including clinics, home healthcare, and hospitals frames adoption pathways and training requirements for new therapies. Taken together, these segmentation insights suggest that successful product strategies must be tailored across indication-specific clinical needs, differentiated molecule classes, pragmatic route and dosage considerations, and channel- and end-user-specific commercialization plans.

Comparative regional perspectives that illuminate regulatory, payer, and infrastructure variations shaping access, adoption, and supply strategies across global markets

Regional dynamics are pivotal in shaping development priorities and market access strategies, reflecting differences in regulatory frameworks, healthcare delivery systems, and patient demographics. In the Americas, strong clinical research infrastructure, established payer systems, and advanced specialty care networks support the uptake of innovative biologics and complex therapeutic regimens, while also presenting stringent evidence requirements and pricing pressures. As a result, manufacturers must prioritize robust clinical endpoints and health economics evidence to secure formulary placement and reimbursement in these markets.

In Europe, Middle East & Africa, regulatory diversity and varied reimbursement environments create both opportunities and challenges. Western European markets tend to demand comprehensive comparative effectiveness data and value-based narratives, while emerging markets in the region may prioritize affordability and supply chain reliability. Meanwhile, the Middle East and Africa present growth potential tied to expanding healthcare infrastructure and rising chronic disease burden, yet they require tailored access strategies and sensitivity to local procurement processes. Coordinated regional approaches that balance centralized evidence generation with localized commercialization tactics are therefore essential.

Across Asia-Pacific, rapid growth in healthcare investment, an expanding biologics manufacturing base, and evolving regulatory frameworks are key themes. Several markets in the region are enhancing local clinical trial capabilities and accelerating approvals for novel therapies, which can shorten time-to-market when regulatory strategies are well aligned. Nevertheless, price sensitivity and diverse reimbursement mechanisms necessitate flexible pricing and partnership models. In sum, regional strategies must account for distinct regulatory expectations, payer behaviors, and healthcare delivery infrastructures to convert scientific advances into accessible patient care.

A synthesis of corporate strategies and ecosystem partnerships that reveal how innovation, manufacturing, and digital integration are reshaping competitive advantage in the sector

Company-level dynamics in gastrointestinal therapeutics reflect a spectrum of strategic postures from innovation-focused biotechs to large-scale manufacturers and specialized contract service providers. Innovator organizations concentrate on advancing next-generation biologics, targeted small molecules, and microbiome-based interventions, often leveraging precision medicine approaches and biomarker-driven trials to delineate responder populations. These companies frequently pursue strategic partnerships with clinical research networks and academic centers to accelerate proof-of-concept studies and to validate differentiated clinical endpoints.

Meanwhile, established pharmaceutical manufacturers and generic producers are optimizing portfolios through life-cycle management, biosimilar development, and formulation enhancements that improve patient convenience and adherence. Contract manufacturing organizations and specialty CDMOs are expanding capacity to support both injectable biologics and complex oral formulations, which affects speed-to-market and cost structures for sponsors. Across the ecosystem, strategic alliances, licensing deals, and targeted acquisitions remain common mechanisms to complement internal capabilities and to fill pipeline gaps.

Finally, emerging companies and digital health entrants are integrating remote monitoring, patient-reported outcomes, and adherence technologies into product offerings, thereby enhancing real-world evidence collection and value demonstration. Collaboration between therapeutic developers and digital partners is strengthening post-market surveillance and payer negotiations. In aggregate, companies that blend scientific differentiation with operational excellence, payer-aligned evidence strategies, and agile commercialization models will be better positioned to succeed within this competitive landscape.

Operationally focused recommendations that integrate supply chain resilience, evidence alignment, and delivery innovation to strengthen clinical and commercial outcomes in gastrointestinal therapeutics

Industry leaders should adopt a set of pragmatic actions to convert scientific progress into durable commercial outcomes and improved patient care. First, prioritize supply chain resilience by diversifying suppliers of critical active pharmaceutical ingredients and negotiating flexible contracts to mitigate tariff-related and geopolitical risks. Investing in dual-source strategies and strengthening relationships with contract manufacturers will decrease vulnerability and preserve continuity of clinical and commercial supply.

Second, align clinical development with payer expectations through early engagement on endpoints, health economics, and real-world evidence generation. Implement adaptive trial designs and pragmatic studies that reflect clinical practice patterns; this will facilitate value conversations and support formulary negotiations. Third, accelerate delivery innovation by optimizing dosage forms and routes of administration that improve adherence and enable home-based care, while also exploring companion diagnostic strategies to target therapies to likely responders.

Fourth, pursue strategic collaborations that combine strengths across biologics development, microbiome science, and digital health to build differentiated evidence packages and patient support solutions. Fifth, adopt flexible commercialization models that tailor distribution strategies to local channel dynamics, balancing hospital pharmacy partnerships with retail and online pharmacy access where appropriate. Finally, enhance organizational capabilities in regulatory strategy, market access, and commercial analytics to ensure swift adaptation to policy shifts and evolving payer demands. Collectively, these steps will strengthen market positioning and improve patient outcomes.

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and scenario analysis to validate strategic insights and recommendations

The research methodology underlying this analysis integrated multiple evidence streams and iterative validation steps to ensure robustness and relevance. Initially, comprehensive secondary research synthesized peer-reviewed clinical literature, regulatory guidance, patent filings, and treatment guidelines to establish a factual baseline for therapeutic mechanisms, clinical endpoints, and standard-of-care practices. This foundational work identified key knowledge gaps and informed subsequent primary research priorities.

Primary research included structured interviews with clinical experts, payer representatives, manufacturing specialists, and commercial leaders to capture contemporary practice patterns, pricing and reimbursement perspectives, and operational constraints. Insights from these interviews were triangulated with regulatory filings and published clinical trial results to validate assertions and to reconcile divergent viewpoints. In addition, scenario analyses were applied to assess supply chain contingencies and policy impacts, enabling exploration of plausible responses to tariff changes and manufacturing disruptions.

Quality assurance measures involved cross-validation of sources, peer review by subject-matter experts, and transparent documentation of assumptions and limitations. Ethical considerations included confidentiality protections for interview participants and adherence to data privacy standards. While every effort was made to ensure comprehensive coverage, users should interpret insights in the context of evolving clinical evidence and policy developments. The methodology thus combines rigorous literature synthesis, stakeholder engagement, and analytic modeling to produce actionable intelligence for decision-makers.

A concise conclusion that synthesizes strategic imperatives and reinforces the need for integrated, regionally aware approaches to convert innovation into patient impact

In conclusion, the gastrointestinal therapeutics landscape is being reshaped by converging forces: scientific innovation in biologics and microbiome research, regulatory emphasis on real-world evidence, evolving payer expectations for value, and operational pressures stemming from supply chain and policy changes. Navigating these shifts requires integrated strategies that span early clinical design, manufacturing planning, and market access negotiations. Organizations that proactively align evidence generation with payer needs, diversify supply chains, and invest in delivery innovation will secure competitive advantage while enhancing patient outcomes.

Moreover, regional nuances in regulatory and reimbursement environments mean that a one-size-fits-all approach is insufficient. Tailored regional strategies, agile manufacturing footprints, and collaborative partnerships will be critical to achieving both clinical impact and commercial sustainability. The cumulative effect of these actions is to create a more resilient and patient-centered therapeutic ecosystem that can respond to policy shifts and evolving clinical practice.

Stakeholders are therefore encouraged to convert these strategic imperatives into concrete initiatives-prioritizing projects that demonstrate clinical differentiation, operational robustness, and clear value to payers and providers. Doing so will accelerate the translation of scientific breakthroughs into accessible, effective therapies for patients living with gastrointestinal diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Diseases Therapeutics Market, by Indication

  • 8.1. Acid-Related Disorders
    • 8.1.1. Dyspepsia
    • 8.1.2. Gastroesophageal Reflux Disease
    • 8.1.3. Peptic Ulcer Disease
  • 8.2. Infectious Gastroenteritis
    • 8.2.1. Bacterial Gastroenteritis
    • 8.2.2. Parasitic Infections
    • 8.2.3. Viral Gastroenteritis
  • 8.3. Inflammatory Bowel Disease
    • 8.3.1. Crohn's Disease
    • 8.3.2. Ulcerative Colitis
  • 8.4. Irritable Bowel Syndrome
    • 8.4.1. Constipation-Predominant
    • 8.4.2. Diarrhea-Predominant
    • 8.4.3. Mixed Type

9. Gastrointestinal Diseases Therapeutics Market, by Drug Class

  • 9.1. Aminosalicylates
  • 9.2. Antibiotics
    • 9.2.1. Ciprofloxacin
    • 9.2.2. Metronidazole
    • 9.2.3. Rifaximin
  • 9.3. Antidiarrheals
  • 9.4. Antispasmodics
  • 9.5. Biologics
    • 9.5.1. Anti Integrin Agents
    • 9.5.2. Anti Tumor Necrosis Factor Agents
    • 9.5.3. Interleukin Inhibitors
  • 9.6. H2 Receptor Antagonists
  • 9.7. Laxatives
  • 9.8. Proton Pump Inhibitors

10. Gastrointestinal Diseases Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Gastrointestinal Diseases Therapeutics Market, by Dosage Form

  • 11.1. Injectable Solution
  • 11.2. Oral Powder
  • 11.3. Oral Suspension
  • 11.4. Tablet Capsule

12. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Gastrointestinal Diseases Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Healthcare
  • 13.3. Hospital

14. Gastrointestinal Diseases Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gastrointestinal Diseases Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gastrointestinal Diseases Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Gastrointestinal Diseases Therapeutics Market

18. China Gastrointestinal Diseases Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AbbVie Inc.
  • 19.7. Amgen Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bausch Health Companies Inc.
  • 19.10. Bayer AG
  • 19.11. Biogen Inc.
  • 19.12. Boehringer Ingelheim International GmbH
  • 19.13. Bristol-Myers Squibb Company
  • 19.14. Cipla Limited
  • 19.15. Dr. Reddy's Laboratories Ltd.
  • 19.16. Eli Lilly and Company
  • 19.17. F. Hoffmann-La Roche Ltd
  • 19.18. Ferring B.V.
  • 19.19. Gilead Sciences, Inc.
  • 19.20. GSK plc
  • 19.21. Johnson & Johnson
  • 19.22. Merck & Co., Inc.
  • 19.23. Novartis AG
  • 19.24. Novo Nordisk A/S
  • 19.25. Organon & Co.
  • 19.26. Pfizer Inc.
  • 19.27. Sanofi S.A.
  • 19.28. Sun Pharmaceutical Industries Limited
  • 19.29. Takeda Pharmaceutical Company Limited
  • 19.30. Teva Pharmaceutical Industries Ltd.
  • 19.31. UCB SA
  • 19.32. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 262. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 265. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC GASTROINTESTINAL DIS